Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer

Zorawar S. Noor,Jonathan W. Goldman,William E. Lawler,Bijoy Telivala,Fadi Braiteh,Brian A. DiCarlo, Kathleen Kennedy,Brad Adams,Xiaoyan Wang,Benjamin Jones,Dennis J. Slamon,Edward B. Garon

Lung Cancer（2019）

引用 6|浏览38

暂无评分

摘要

•The maximum tolerated dose of luminespib is 55 mg/m2 when given in combination with pemetrexed at 500 mg/m2.•The objective response rate was 14% amongst patients treated at the maximum tolerated dose.•Tolerability of luminespib plus pemetrexed is limited by ocular toxicity.

查看译文

关键词

Luminespib (AUY922),Heat Shock Protein 90 (HSP90) Inhibitor,Non-small cell lung cancer (NSCLC),Dihydrofolate Reductase (DHFR),Targeted therapy,Pemetrexed

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要